摘要
目的探讨帕瑞昔布钠在肝癌肝切除术患者术后应用中的镇痛效果。方法回顾性收集东方肝胆外科医院2015年6—12月的肝癌肝切除术病例共200例,根据术后是否使用帕瑞昔布钠分成两组(治疗组100例,对照组100例)。治疗组在术后应用帕瑞昔布钠干预(术后6、18、30h分别缓慢静推帕瑞昔布钠40mg),对照组不予帕瑞昔布钠干预,两组术后均使用舒芬太尼镇痛泵静脉维持(治疗组剂量减少),比较两组患者手术后的疼痛程度(VAS评分)及术后不良反应的发生情况,并进行统计学分析。结果治疗组的VAS评分明显低于对照组,术后不良反应的发生率明显低于对照组,差异有统计学意义(P<0.05)。结论帕瑞昔布钠作为一种新型注射用选择性COX-2抑制剂,可以显著减少术后阿片类药物用量及其相关不良反应,值得在术后镇痛方面进行推广。
Objective To investigate the analgesia effects of dynastat in hepatic cancer patients after liver resection. Methods From June to December of year 2015, we collected 200 cases of hepatic cancer operation in the Eastern Hepatobiliary Surgery Hospital retrospectively. Those patients were divided into 2 groups （the dynastat treated group, n= 100; the untreated group, n = 100）. The patients in treated group were given dynastat 3 times （40 mg/5 ml,iv, 6 hours, 18 hours and 30 hours after operation respectively）, while the control group did not received any dynastat. The sufentanil analgesia pumps were used in both groups. The treated group received a lower sufentanil dose. The pain severity （VAS score） of patients and the postoperative untoward effects were compared between these two groups. The results were analyzed statistically. Results The VAS score and the postoperative untoward effects of the treated group were clearly lower than the control group. All differences have statistical significance（P〈0.05） Conclusions As a new-type selective COX-2 inhibitor for injection, dynastat can reduce the dosage and side effects of opioid medicine. It deserves to be popularized in post operation analgesia.
出处
《药学实践杂志》
CAS
2017年第1期73-74,81,共3页
Journal of Pharmaceutical Practice
